川牛膝醇提物降压作用机理的实验研究
|
摘要
原发性高血压病是一种严重影响人类健康和生活质量的疾病。本病的发病率今年来呈上升趋势,现代医学对本病的研究已较深入,但仍有很多存在争议和未研究的问题存在,大量学者正为之不懈努力。中医学对本病的深入认识和理解是伴随中西医结合而逐步实现的,但至今尚无公认的系统化理论。临床上存在很多见解,多根据辨证论治的原则来治疗此病,已积累了大量的经验并取得了可喜的成果。
原发性高血压病机极为复杂,因此临床难于辨证或用药难于取效。导师盖国忠教授认为本病的病位在血脉,病机关键是气血失和,血随气逆。牛膝醇提物就是在此理论指导下完成的,已在临床应用多年,取得较好的临床效果。为了进一步阐明牛膝的降压效果及有关机制,予以客观的,科学的论证。本实验以原发性高血压大鼠(SHR)为研究对象,此模型为国际上公认的与人类原发性高血压病最为接近的动物模型。通过对SHR的血压、血清超氧化物歧化酶(SOD)、丙二醛(MDA)的含量的影响;肾组织转化生长因子(TGF-β1)蛋白表达的影响;对体外培养血管内皮细胞影响;对血浆前列环素(PGI2)浓度影响的实验研究。对大鼠胸主动脉内皮细胞相关mRNA的表达的影响的实验研究。
实验结果显示:
1、川牛膝醇提物能够降低自发性高血压大鼠(SHR)的血压;
2、川牛膝醇提物能明显降低大鼠血清MDA含量同时显著升高SOD活性;
3、川牛膝醇提物可明显降低肾组织细胞中TGF-β1蛋白的表达;
4、能够调节SHR血管活性物质生成和释放,升高血浆PGI2含量;
5、川牛膝药物血清有促进体外培养大鼠胸主动脉血管内皮细胞增值作用;
6、能够有效预防和修复LPS对血管内皮细胞的损伤。
7、牛膝血清高、中剂量组可明显影响大鼠胸主动脉内皮细胞相关mRNA的表达
本研究探讨了川牛膝部分作用机理,为认识和研究原发性高血压病的理论与方药提供了一定的依据,我们期待着更深入的研究与探讨。
The primary hypertension is one kind of the disease affecting human being health and the quality of life gravely. The morbidity falling ill originally assumes an uptrend since the beginging of this year , the modern medicine research to the disease is already more thorough , still there are existence , large amount of scholar there existing dispute and the problem not having studied in many being that unremitting efforts but. Knowing and understanding traditional Chinese medical science to going deep into falling ill originally is to accompany integration of Chinese and western medicine but to come true step by step , there is no so far still but universally accepted systematization theory. Mount existence clinically many view, many disease coming to cure this the principle according to the diagnosis and treatment based on an overall analysis of the illness and the patient's condition, already have accumulated large amount of experience.and have got gratifying achievement.
Primary hypertension machine is extremely complicated , therefore clinical medicine difficult to discriminate or use is difficult to take an effect. The faithful director Gai guo zhong professor thinks that the disease place falling ill originally is in a blood vessel in which the blood and qi circulate , pathogenesis key is that gas blood becomes estranged , blood goes against with the gas. The root of bidentate achyranthes formulating is completed under being that here theory guides, already in applying many years clinically, get fairly good clinical effect. Expound and prove for expounding the root of bidentate achyranthes decompression effect further and giving the objective's , science's in connection with mechanism. The experiment takes primary hypertension rat (SHR) as the animal model studying the marriage partner , this model are universally accepted go ahead between nations and the primary hypertension of human being approaches most. Pass the effect to SHR rat blood pressure , serum superoxide dismutase (SOD) , third dialdehyde (MDA) contents; Effect kidney organization conversion growth factor (TGF-β1) egg white is expressed; To extracorporeal culture blood vessel bast, the cell affects; The experiment that thickness affects to blood plasma PGI2 studies.
The experiment bear fruit is demonstrated:
1. the ethanol extracts from Cyathula officinalis Kuan is a thing being able to reduce spontaneity hypertensionrat (SHR) blood pressure;
2.the ethanol extracts from Cyathula officinalis Kuan is a thing being able to reduce rat serum MDA contents at the same time notable power-ups SOD activity obviously;
3. the ethanol extracts from Cyathula officinalis Kuan id a thing but reduces expressing of kidney organization cell middle TGF-β1 ;
4. Being able to adjust SHR blood vessel active material coming into being and releasing , elevates blood plasma PGI2 contents;
5.the ethanol extracts from Cyathula officinalis Kuan has promoting the extracorporeal culture rat chest aorta blood vessel bast cell added value effect;
6.Being able to have an effect to take precautions against and restore the LPS loss to blood vessel
7. In the root of bidentate achyranthes serum height, dosages may affect rat chest aorta bast cell relevance mRNA expressing obviously setthe ethanol extracts from Cyathula officinalis Kuan part effect mechanism having studied investigation and discussion originally, has provided the certain basis , our in expectation of more thorough research and investigation and discussion to the medicine knowing and studying primary hypertension theory and method.
原发性高血压病机极为复杂,因此临床难于辨证或用药难于取效。导师盖国忠教授认为本病的病位在血脉,病机关键是气血失和,血随气逆。牛膝醇提物就是在此理论指导下完成的,已在临床应用多年,取得较好的临床效果。为了进一步阐明牛膝的降压效果及有关机制,予以客观的,科学的论证。本实验以原发性高血压大鼠(SHR)为研究对象,此模型为国际上公认的与人类原发性高血压病最为接近的动物模型。通过对SHR的血压、血清超氧化物歧化酶(SOD)、丙二醛(MDA)的含量的影响;肾组织转化生长因子(TGF-β1)蛋白表达的影响;对体外培养血管内皮细胞影响;对血浆前列环素(PGI2)浓度影响的实验研究。对大鼠胸主动脉内皮细胞相关mRNA的表达的影响的实验研究。
实验结果显示:
1、川牛膝醇提物能够降低自发性高血压大鼠(SHR)的血压;
2、川牛膝醇提物能明显降低大鼠血清MDA含量同时显著升高SOD活性;
3、川牛膝醇提物可明显降低肾组织细胞中TGF-β1蛋白的表达;
4、能够调节SHR血管活性物质生成和释放,升高血浆PGI2含量;
5、川牛膝药物血清有促进体外培养大鼠胸主动脉血管内皮细胞增值作用;
6、能够有效预防和修复LPS对血管内皮细胞的损伤。
7、牛膝血清高、中剂量组可明显影响大鼠胸主动脉内皮细胞相关mRNA的表达
本研究探讨了川牛膝部分作用机理,为认识和研究原发性高血压病的理论与方药提供了一定的依据,我们期待着更深入的研究与探讨。
The primary hypertension is one kind of the disease affecting human being health and the quality of life gravely. The morbidity falling ill originally assumes an uptrend since the beginging of this year , the modern medicine research to the disease is already more thorough , still there are existence , large amount of scholar there existing dispute and the problem not having studied in many being that unremitting efforts but. Knowing and understanding traditional Chinese medical science to going deep into falling ill originally is to accompany integration of Chinese and western medicine but to come true step by step , there is no so far still but universally accepted systematization theory. Mount existence clinically many view, many disease coming to cure this the principle according to the diagnosis and treatment based on an overall analysis of the illness and the patient's condition, already have accumulated large amount of experience.and have got gratifying achievement.
Primary hypertension machine is extremely complicated , therefore clinical medicine difficult to discriminate or use is difficult to take an effect. The faithful director Gai guo zhong professor thinks that the disease place falling ill originally is in a blood vessel in which the blood and qi circulate , pathogenesis key is that gas blood becomes estranged , blood goes against with the gas. The root of bidentate achyranthes formulating is completed under being that here theory guides, already in applying many years clinically, get fairly good clinical effect. Expound and prove for expounding the root of bidentate achyranthes decompression effect further and giving the objective's , science's in connection with mechanism. The experiment takes primary hypertension rat (SHR) as the animal model studying the marriage partner , this model are universally accepted go ahead between nations and the primary hypertension of human being approaches most. Pass the effect to SHR rat blood pressure , serum superoxide dismutase (SOD) , third dialdehyde (MDA) contents; Effect kidney organization conversion growth factor (TGF-β1) egg white is expressed; To extracorporeal culture blood vessel bast, the cell affects; The experiment that thickness affects to blood plasma PGI2 studies.
The experiment bear fruit is demonstrated:
1. the ethanol extracts from Cyathula officinalis Kuan is a thing being able to reduce spontaneity hypertensionrat (SHR) blood pressure;
2.the ethanol extracts from Cyathula officinalis Kuan is a thing being able to reduce rat serum MDA contents at the same time notable power-ups SOD activity obviously;
3. the ethanol extracts from Cyathula officinalis Kuan id a thing but reduces expressing of kidney organization cell middle TGF-β1 ;
4. Being able to adjust SHR blood vessel active material coming into being and releasing , elevates blood plasma PGI2 contents;
5.the ethanol extracts from Cyathula officinalis Kuan has promoting the extracorporeal culture rat chest aorta blood vessel bast cell added value effect;
6.Being able to have an effect to take precautions against and restore the LPS loss to blood vessel
7. In the root of bidentate achyranthes serum height, dosages may affect rat chest aorta bast cell relevance mRNA expressing obviously setthe ethanol extracts from Cyathula officinalis Kuan part effect mechanism having studied investigation and discussion originally, has provided the certain basis , our in expectation of more thorough research and investigation and discussion to the medicine knowing and studying primary hypertension theory and method.
引文
[1]邓铁涛.高血压病辨证论治的体会[J].新中医,1980,(2):10.
[2]董振华,范爱平.祝谌予教授治疗高血压病的经验介绍[J].中国医刊,1999,34(8):44-45.
[3]丁有钦.高血压病的中西医诊治[J].新中医,2000,32(10):40.
[4]陈四清.育阴潜阳、调气行血法治疗高血压病[J].江苏中医药,2004,25(12):41.
[5]严季澜.高血压病中医治疗.北京:中国医药科技出版社,1992:81.
[6]徐树楠,刘海丽.高血压病的中医病理学特点探微[J].中国中医基础医学杂志,2003,9(9):10.
[7]吴辉,冼绍祥,黄衍寿.血管活性物质与原发性高血压中医证型的关系[J].四川中医,2000,18(19):11.
[8]邓旭光.高血压病中医病机若干问题探讨[J].中医杂志,2001,42(4):197-199.
[9]陆广莘.高血压病中西医结合研究中的辨病和辨证问题[J].中医杂志,1980,21(5):11.
[10]孔炳耀.气血理论在高血压病研究中的应用[J].中国中医基础医学杂志,1998,4(9):52.
[11]李青鸟.原发性高血压病病因之我见[J].光明中医,2000,15(1):8-11.
[12]段学忠.益气活血法治疗老年高血压病的研究[J].山东中医药大学学报,1997,21(6):123.
[13]祝建华.从脾胃论治高血压病56例[J].四川中医,1997,15(1):26-27.
[14]邓铁涛.邓铁涛临床经验集要.北京冲国医药科技出版社,1981.
[15]郭乃光.健脾化湿法治疗无症状性高血压病30例[J].新中医,2000,32(10):35.
[16]邓旭光.高血压病中医病机若干问题探讨[J].中医杂志,2001,42(4):197-199.
[17]刘治主,牟建军.高血压病诊断治疗学.北京:北京医科大学,中国协和医科大学联合出版社,1998:16.
[18]王永先.中国内科学.上海:上海科学技术出版社,1997:337-342.
[19]李运伦,程立新.高血压病的病机病理刍议[J].中医研究,2000,13(1):7-8.
[20]冉旭.高血压病的病机探讨[J].湖北中医杂志,2002(3):11-12.
[21]龚一萍.以肝为中心论治高血压病的理论探讨[J].中国中医基础医学杂志,2000,6(11):29-30.
[22]衷敬柏,钱红宇,王英奇.105例中老年高血压病虚实分析[J].陕西中医,1996,17(3):103-104.
[23]柴瑞霁.柴浩然治疗高血压病的经验.山西中医,1994,10(4):10.
[24]肖梅芳.周端应用活血潜阳法治疗高血压病经验.上海中医药杂志,2004,38(4):12.
[25]李运伦.清热降压方治疗高血压病临床效应的比较研究[J].山东中医药大学学报,2001,25(1):18.
[26]李运伦.清旰宁心泻心解毒法治疗高血压病的探讨[J].山东中医药大学学报,2002,26(1):20.
[27]李运伦.高血压病气虚证证治规律探讨[J].山东中医杂志,2001,20(1):9-11.
[28]范平.温阳化瘀法治疗老年高血压病探析[J].山东中医杂志,1998,17(6):486.
[29]古炽明,丁有钦.高血压病证候文献分析述评[J].中医药学刊,2003,21(7):1156-1157.
[30]尚春生.温阳法治疗高血压病40例临床报道[J].实用中医内科杂志,1999,20(3):11.
[31]钱岳晟,张伟忠,周怀发,等.原发性高血压患者表型与中医体质分类关系的研究[J].中国中医基础医学杂志,2002,8(2):49.
[32]鞠大宏,韩学杰,谢雁鸣,等.高血压病从络论治探讨[J].中国中医基础医学杂志,2001,7(9):43.
[33]岳桂华,盖欣,张爱珍.自组织理论与高血压病初探[J].山东中医杂志,1999,18(6):245-246.
[34]蔡光先,朱克俭,韩育明,等.高血压病常见证候临床流行病学观察[J].中医杂志,1999,40(8):492.
[35]郑峰,胡世云,郭进建,等.高血压病中医辨证分析[J].河北中医,2000,22(9):651.
[36]袁成民,江涛.高血压病中医药研究进展[J].山东中医药大学学报,2002,26(3):235.
[37]刘小斌.邓铁涛教授诊疗经验整理研究[J].新中医,1998,30(3):6.
[38]丁有钦.高血压病的中西医诊治[J].新中医,2000,32(10):40.
[39]李运伦,曲政军.活血化瘀治疗高血压病的机理[J].山东中医药大学学报,1998,22(1):23.
[40]李运伦.黄连解毒汤加减治疗高血压病30例临床研究[J].国医论坛.2000,15(2):38-39.
[41]李运伦.理脾化湿法治疗原发性高血压35例[J].陕西中医,2004,25(2):136.
[42]高振华.高泳江辨治高血压病的经验.中医杂志,1997,38(11):654-655.
[43]雄上中,徐小周.辨证治疗老年高血压120例[J].四川中医,2001,8(19):38.
[44]张亚玲.高血压的辨证分型论治[J].衡阳医学院学报,1999,27(3):350.
[45]祝建华.从脾胃论治高血压病56例[J].四川中医,1997,15(1):26.
[46]甘业崇.镇肝熄风汤治疗轻中度高血压病157例[J].中国民间疗法,2005,13(1):53.
[47]蔡昌龙,李明月,邢之华等.天麻钩藤饮对肝阳上亢型高血压病患者血浆SOD、MDA的影响[J].家用医学杂志,2005,21(3):321.
[48]刘应柯,刘尚玲,郭桐生.参龙降压灵对自发性高血压大鼠血压及血浆ET、CGRP 含量的影响[J].第一军医大学学报,2000,20(2):180.
[49]李建平,严灿,邓中炎.活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究[J].中医杂志,2000,41(5):301.
[50]连娜,连秀峰,谢人明,等.心压平胶囊治疗高血压病的药效学研究[J].西北药学杂志,2000,15(1):17.
[51]吴伟,刘煜德,陈宏硅,等.补肾益心片对肾血管性高血压大鼠的降压作用及保护靶器官的研究[J].广州中医药大学学报,2001,18(1):63.
[52]刘守义,李秀芳,刘书宇,等.二麻降压冲剂降压作用的实验研究[J].中国中医药信息杂志,1999,5(9):22.
[53]廖圣宝,刘光伟,张雪冰,等.滋水降火饮对肾性高血压大鼠血清细胞因子水平的影响[J].中医药学报,2001,29(3):61.
[54]段学忠,杨丁友,孙西庆.益脉降压流浸膏对老年高血压患者血小板活化纤溶活性 及血管紧张素的影响[J].中国中西医结合杂志,2000,7(9):36.
[55]袁成民.八物降压冲剂治疗原发性高血压的临床及实验研究[J].山东中医药大学学报,1999,23(3):189.
[56]赖益忠.六味地黄丸(汤)现代研究新进展.中医药信息,1999,16(1):13.
[57]宋和鉴,钱世明,刑俊武.血压平滴鼻剂对自发性高血压大鼠血浆肾素血管紧张素的影响[J].中医药研究,2000,16(2):50-51.
[58]李武明,何香,谭元牛.复方杜仲降压片治疗高血压病45例分析[J].中医药学刊,2004,22(2):331-332.
[59]唐树德.首乌治疗早期肾脏损害血瘀型高血压患者28例[J].中国中西医结合杂志,1994,(5):302.
[60]潘志敏,经京,吕圭源.“血灵”的抗高血压临床研究及意义[J].浙江中医学院学报,1993,(6):31.
[61]罗伟.葛根素治疗高血压病的临床研究[J].中国中医基础医学杂志,2000,6(5):61.
[62]罗伟,李保东,杨瑞华,等.葛根素对高血压初患者血浆内皮素及血栓B_2、6-酮-前列腺素F_(1a)含量的影响[J].中国中西医结合杂志,2000,20(1):68-69.
[63]冯培芳,等.三七总皂甙改善高血压病左室舒张功能的临床研究.浙江中西医结合杂志,1996;6(2):65.
[64]龚铭,廖晓阳,辛茂顺.醋柳黄酮对高血压有利钙及胰岛素敏感性的影响[J].现代中西医结合杂志,2000,9(14):1303-1306.
[65]王鸿博.灯盏花对老年原发性高血压患者早期肾功能的影响J].现代中西医结合杂志,2000,9(18):1744-1745.
[66]施易安.足三里注射治疗高血压病40例[J].天津中医,2000,17(6):25.
[67]张登部,刘国真,侯凤琴,等.康为电子灸足三里对高血压患者血流变学及血压影响的观察[J].中国针灸,2000:685-686.
[68]刘幸娟.耳尖放血合耳穴贴压治疗高血压病[J].湖北中医杂志,2000,22(1):47.
[69]胡爱香,陈秀荣,杨永枝.足浴并按摩治疗高血压病40例.中医研究,2000,13(4):55.
[70]刘苏生.针刺人迎穴为主治疗高血压病56例.天津中医,2000,17(2):30.
[71]谢云.针刺耳压治疗原发性高血压病临床观察.中国针灸,2000,20(6):335-336.
[72]徐巧云,孙鸿杰.血液磁极化疗法治疗原发性高血压病143例疗效观察.中国实用内科杂志,2000,20(8):484-486.
[73]江苏新医学院 中药大辞典[M]上海:上海人民出版社,1977:2024.
[74]甄攀.粉防已碱的研究进展[J].张家口医学院学报,2004,21(2):79.
[75]黄志宏,汤泰秦,黄纳斯,等.川芎嗪对缺氧肺动脉高压大鼠血浆内皮素、降钙素基因相关肽水平的影响[J].广州中医药大学学报,1998,15(4):275-276.
[76]王峰,刘敏,杨连春,等.咖啡酸阿魏酸对高血压大鼠的降压作用[J].解放军药学学报,1999,15(5):1-4.
[77]王秋月,康健,李尔然,等.白花前胡提取物对缺氧性肺动脉高压病人血浆内皮素-1的影响[J].中国医科大学学报,2001,30(1):82-83.
[78]刘发,魏苑,杨新中.红花黄素对高血压大鼠的降压作用及对肾素、血管紧张素的影响[J].药学学报,1992,27(10):785.
[79]李志淮,杜冠华,张均田.丹酚酸A对高血压大鼠钠钾ATP酶活性的作用[J].中国中医药科技,1997,4(1):32.
[80]唐忠志,唐瑛.丹参对自发性高血压大鼠左室心肌病变及血液流变学的影响[J].第四军医大学学报,2004,25:100-103.
[81]程俊彦,熊玮,郑智,等.丹参逆转自发性高血压大鼠左室肥厚及其对血管紧张素Ⅱ受体1表达的影响[J].中国中西医结合急救杂志,2004,11:99-103.
[82]程俊彦,卢中秋,李章平,等.丹参预防自发性高血压大鼠左室肥厚及其对clos表达的影响[J].中国临床药理学与治疗学,2004,9:807-810.
[83]占成业,陶秀良,田橙,等.细胞黏附分子1在高血压左室肥厚发病中的作用及丹参酮ⅡA对其表达的影响[J].中国中西医结合急救杂志,2004,11:208-211.
[84]邓杰,熊玮,郑智.丹参对自发性高血压大鼠心肌细胞凋亡及基因蛋白表达的影响[J].江西医药,2003,38:322-324.
[85]李景新,薛冰,陈连璧.沙苑子总黄酮对高血压大鼠的降压作用及血管紧张素含量的影响[J].中国药理学与毒理学杂志,2002,16(5):338-339.
[86]耿秀芳,李桂芝,王守训.银杏叶总黄酮对ACE的活性的影响[J].吉林中医药,1993,(6):37.
[87]贺师鹏,靖宇,岳保珍.甘草次酸与大鼠肝膜血管紧张素Ⅱ受体相结合[J].中国药理学通报,1998,14(5):19-21.
[88]李连达.抗心肌缺血中药研究进展[J].中国中西医结合杂志,1987,7:57.
[89]刘祥秀,孔德明,张雅丽.单味中药黄芪对胰岛素抵抗并高血压防治作用的实验研究[J].贵阳中医学院学报.2005,21(1):22.
[90]贾月霞,时安云.枸杞多糖对肾性高血压大鼠血管活性物质的影响[J].北京医科大学学报.1997,29(5):429-432.
[91]陈素红,吕圭源,施斌,等.复方决明提取物的降压作用机制研究.中草药,2004,35(2):180.
[92]菪忠志,王启全,陈文敏,等.丹参对自发性高血压大鼠心肌Ⅰ和Ⅲ型胶原及局部醛固酮的影响[J].中华实用医学,2002,4(11):25.
[93]宋纯清,樊懿,黄伟晖,等.钩藤中不同成分降压作用的差异[J].中草药,2000,31(10):762.
[94]孔晓龙,蒋伟哲,黄仁彬,等.龙眼参对自发性高血压大鼠和SD大鼠血压的影响[J].中草药,2001,32(8):727-729.
[95]刘建斌,任江华.钩藤对自发性高血压大鼠心肌重构及原癌基因C-fos表达的影响[J].中国中医基础医学杂志.2000,6(5):40
[96]香川珠实.罗布麻叶提取物的降压作用[J].Natural Medicines.2004,58(3):109-112.
[97]玉从容,吕俊华.葛根素对胰岛素抵抗高血压模型大鼠血压和肾素血管紧张素系统的影响[J].四川中医,2005,23(4):20-22.
[98]关玉生.天麻钩藤饮治疗原发性高血压患者内皮素、降钙素基因相关肽的变化的研究[J].中药药理与临床,1997,13(6):45.
[99]刘保国,白宝银,施海法,等.加昧天麻钩藤饮对阴虚阳亢型高血压患者血浆ET、PRA、AngⅡ的影响[J].中国全科医学杂志,2000,3(3):190-191.
[100]龚一萍,倪美文,宋霄红.天麻钩藤饮对高血压肝阳上亢证大鼠胰岛素抵抗影响的实验研究[J].浙江中医学院学报,2005,29(2):62-64.
[101]金龙,周文泉.络活胶囊治疗痰瘀阻络型高血压病的临床研究[J].中国中西医结合杂志,2004,24(7):610-612.
[102]杨兴才.羚羊角治疗高血压病的临床研究[J].辽宁中医杂志,2004,31(11):911-912.
[103]周端,苑素云,顾仁提,等.活血潜阳胶囊改善高血压病血管重建的临床与实验研究[J].中国医药学报,2001,16(4):70-71.
[104]陈可冀.血府逐瘀滴丸防治血管成形术后再狭窄的研究[J].中国中医药科技,1997,4(3):173.
[105]宋和鉴,钱士明,邢俊武.血压平滴鼻剂对自发性高血压大鼠血压血浆肾素血管紧张素的影响[J].中医药研究,2000,16(2):50-51.
[106]李建平,严灿,邓中炎,等.活血祛痰治法及其组方预防自发性高血压大鼠心肌纤维化的实验研究[J].中医研究,1999,12(6):9-11.
[107]马杰,王普民,胡丽萍,等.心脑静片对实验性脑缺血及高血压的作用研究[J].中草药,2000,31(1):39-40.
[108]段学忠,孙西庆,李丁友.益脉降压流膏降压及调节内皮素与降钙素基因相关肽的实验研究[J].中国中医药科技,2000,7(3):143.
[109]刘文军,刘屏,袁默,等.益肾降压方对肾实质性高血压大鼠肾组织eNOS、ET-1及其mRNA表达的影响研究[J].中华中医药杂志,2005,20(9):528-530.
[110]刘景超,杨新年,肖华云,等.降压调脂胶囊对高血压大鼠血压及血清NO的影响[J].山东中医杂志,2001,20(4):236-237.
[111]贺林,王若光,尤昭玲,等.黄芪丹参注射液对妊娠高血压综合征大鼠血浆一氧化氮及肿瘤坏死因子的影响[J].湖南中医学院学报,2003,23(2):4-5.
[112]李运伦,汤钟娟.黄连清降合剂对自发性高血压大鼠血管平滑肌细胞生长因子表达的影响[J].山东中医药大学学报,2003,27(2):143-144.
[113]廖圣宝,刘光伟,张雪冰,等.滋水降火饮对肾性高血压大鼠血清细胞因子水平的影响[J].中医药学报,2001,29(3):60-61.
[114]夏洪生,田兵,张永峰,等.通脉Ⅰ号对自发性高血压大鼠血压及血管平滑肌细胞增殖的影响[J].深圳中西医结合杂志,2001,11(5):260-263.
[115]刘剑刚,史大卓,汪晓芳,等.愈心梗液对大鼠急性心肌梗死后早期心室重构的影响[J].中国中西医结合急救杂志,2001,8(2):76-78.
[116]罗心平,施海明,曾治宇,等.麝香保心丸对心肌梗塞后左室形态和功能影响的实验研究[J].中成药,2001,23(7):503-505.
[117]舒静,董耀荣.益气活血方治疗心室重构的临床研究[J].江苏中医,2000,21(9):13-15.
[118]潘毅,邓中炎,严灿.心肌康逆转高血压左室肥厚的临床研究[J].中国中医药科技,2001,8(4):213-214.
[119]田相同,赵龙梅.新加钩藤片对高血压病及左室肥厚的影响[J].山东中医杂志,2002,21(6):341-342.
[120]周建中,雷寒,陈运贞,等.灯盏细辛注射液对自发性高血压大鼠心室及血管重构的影响[J].中国中西医结合杂志,2002,22(2):122-125.
[121]王振涛,王硕仁,赵明镜,等.活血和益气方药对心肌梗死后左心衰大鼠左心室重构影响的比较研究[J].中国中西医结合杂志,2002,22(5):376-378.
[122]莫书荣,谢露,张士军.诺迪康对大鼠心肌超微结构的影响[J].广西中医药,2002,25(4):52-53.
[123]侯云生,何振山,齐书英,等.黄芪对急性心肌梗死后左室重构的实验研究[J].中国急救医学,2000,20(7):381-383.
[124]Wang H,Luo S D,Cai H S,et al.Antiarrhythmic effdct of diacetyl-Lineinine[J].Chin H osp Pharm J(中国医院药学杂志),2001,21(6):3281.
[125]Cao F.Huang C X.Jiang H.et al.Effets of diancetyl-Linesi-nine on sodium ion channel and L-type calcium ion channel in isolated ventricular myocytes[J].Med J W uhan Univ(武汉大学学报:医学版),2004,25(4):364-367.
[1266]Wang J L,Nong Y.Effects of Lien sin ine on action poten-tials and Ina,Lca-lin guinea pig ventricular myocytes[J].chin Tradit Herb Drugs(中药学),2000,31(3):194-196.
[127]Guo X G,Chen J Z.Effects of puerarin on L-typecalcium channel in isolated rat ventricularmyocytes[J].china J chin Mater Med(中国中药杂志),2004,29(3):247-250.
[128]Zhuang N N,Li Z C,Zhang A D,et al.The effects of oxy-mat rine on L-type calcium channel in isolated ventricular myocytes of guinea pig[J].Chin J Cardiac Pacing Electrophysiol(中国心脏起搏与心电生理杂志),2004,18(3):209-211.
[129]Sun H L,Xu C Q.Effects of oxymatrine on[Ca2+]in single ventricular myocyte of guinea pig[J].China J N at Med(国国天然药物),2004,39(4):264-266.
[130]Zhu X X,Li L D.The protective effects of vitexiarhamnoside(VR) on the cultured cardiac myocytes damaged by hypoxia and reoxygenation[J].China J N at Med(中国天然药物),2003,1(1):45-47.
[131]QiS Y,Liu K S,Wang Y G,et al.Effects of astragale on L-type calcium current ofr myocytes from rabbit infracted heart[J].Pharrn Chin Mater Med Clin(中国药理与临床),2003,19(1):17-19.
[132]何建国,荆志成,顾晴,等.缺氧性肺动脉高压大鼠泡内肺动脉与右心室胶原表达及黄芪的干预作用[J].中华医学杂志,1999,79(9):654-656.
[133]陈伟,顾仁樾,朱平,等.通心络调控心衰大鼠β受体系统抑制心室重构的实验研究[J].中国中医药科技,2002,9(5):274-275.
[134]邓中炎,严灿,潘毅,等.平肝益气、活血祛痰法逆转自发性高血压大鼠左心室重构的实验研究[J].中国中医药科技,2001,8(2):106-107.
[135]周迎春,赵锋利,陈镜合,等.开心胶囊对大鼠心梗后左室非梗塞区胶原改建的影响[J].广州中医药大学学报,2002,19(3):204-206.
[136]王振涛,王硕仁,李敏,等.活血益气注射液治疗心衰大鼠心气虚证的研究[J].中药药理与临床,2000,16(增刊):73-75.
[137]刘建斌,任江华.钩藤对自发性高血压大鼠心肌重构及原癌基因c-fbs表达的影响.中国中医基础医学杂志,2000,6(5):40-44.
[1]王萍,介建政.高血压流行病学[J].中国乡村医生杂志,2001,8:11.
[2]张维忠.2004年高血压研究的循证医学新进展[J].中国循证医学杂志,2005,5(3):185.
[3]于汇民,王兵,刘国仗.原发性高血压的病因及发病机制[J].新医学2003,34(3):135.
[4]王先梅,杨丽霞.原发性高血压发病机制的研究进展[J].西南国防医药,2005,15(1):98.
[5]沈利亚,仇克难.血管内皮舒张功能不全与高血压关系研究进展[J].江汉大学学报(自然科学版).2004,32(2):86.
[6]Bobik A,Grooms A,Millar T A,et al.Growth factor activity of endothelin on vascular smooth musle[J].Am J physiol,1990,258(3Ptl):408-415.
[7]Ashids T,Kawano Y,Yoshimi H,et al.Effects of ouabain and verapamil on endothelin-1induced contraction of mesenteric artery in young spontaneously hypertensive rats[J]J cardiovasc Pharmacol,1991,17(Suppl7):174-176.
[8]Gottsauner - Wolf M,Molitemo J,Lincoff AM,et al.Restenosis - an open file[J].Clin Cardiol,1996,19(5):347-356.
[9] Chabrier PE. Growth factors and vascular wall [J] . Int Angiol, 1996, 15(2): 100-103.
[10] Miyazaki H, Shibata T, Fujii N. Intracellular signaling pathways of angiotensin II receptor type 1 involved in the development of cardiovascular diseases[J]. Nippon Rinsho, 1998,56(7): 1906-1911.
[11] Inagami T, Eguchi S, Numaguchi K, et al. Cross - talk between angiotensin II receptors and the tyrosine kinases and phosphatases[J]. J Am Soc Nephrol, 1999, 10 (Suppl 11):S57 - 61.
[12] Liu G, Espinosa E, Oemar BS, et al. Bimodal effects of angiotensin II on migration of human and rat smooth muscle cells, direct stimulation and indirect inhibition via transforming growth factor- β 1[J]. Arterioscler Thromb Vasc Biol, 1997, 17(7): 1251 - 1257.
[13] Reaven GM. Role of insuiln in human disease[J]. Diabetes. 1988. 37(12): 1595.
[14] KatakamPV. UjhelyiMR. HoenigME, etal. Endothelialdys function precedes hypertension indiet-induced insulinre-sistance[J]. AmJPhysiol. 1998, 275(3): R788-792.
[15] Schachinger V, Britten MB, Zciher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease[J].Circulation, 2000,101(16):1899～1906.
[16] Vaziri ND, NiZ, Oveisi F, etal. Enhanced nitric oxide in activation and protein nitration by reactive oxygen species in renal insufficiency [J]. Hypertension. 2002,39(1):135～141.
[17] Giuseppe Lembo, Carmine Vecchione, Raffaele Izzo, etal. No radrenergic vasclar hyper-responsiveness in human hypertension is dependent on oxygen free radical impairment of nitric oxide activity [J].Circulation, 2000,102:552～557.
[18] Wassmann S, Laufs U, Baumer AT, et al. HMG CoA reductse inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species [J] Hypertension 2001,37(6):1450～1457.
[19] Lingyun W, Jacques DC. Effects of superoxide on signaling pathways in smooth cells from rats[J] Hypertension, 1999,34:1247—1253.
[20] Michael JR, Markewitz BA, Kohan E. Oxiod ativestress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells .[J] Am J Physiol, 1997, 273 : L768-L774.
[21]Tan Mianshin,Le Yanjiun,Shyijiang,et al.Oxidized low density liprotein stimulated endothelin-1 release and mRNA expression from rat med angial cells.[J]J lab Clin Med,1997,129(2):224-230.
[22]Ortiz MC.Manriquez MC,Romero JC,et al.Antioxidants block angiotenin Ⅱ induced increases in blood pressuer and endothelin.[J]Hypertension,2001 Sep;38(3Pt2):655-659.
[23]Liy.Liu J,Zhan X.Tyrosin ephosphorylation of cortactinisrequired for H2O2 mediated injury of human endothelial cells[J].J Biol Chem,2000,275(47):187-193.
[24]Abe J,Kusulma M,Ulevitch RJ,et al.Big mitogen actived protein kinasel(BKM1) is a redox-sensitive kinase[J].J Biol Chem 1996,273:16586-16590.
[25]Caper IR,Laursen JB,Fukai,et al.Vascular thrombin receptor regulation in hypertension rats[J].CircRes.1997.80:838-844.
[26]Kaikobad I rani.Oxidant sianaling in vascular cell growth,death,and survival,A review of the roles of reactive oxygen species in smooth muscle and endothelial cellmitogenic and apoptic signaling[J].CircRes,2000,87:179-183.
[27]Johns C,Ciavras 1,Handy DE,et al,Models of experimental Hypertension in mice[J].Hypertension,1996,28:1064.
[28]汤健,王瑜.肾素—血管紧张素系统分子生物学研究[J].基础医学与临床,1991,11(3):5-9.
[29]胡芳,肖君华.原发性高血压分子生物学的研究进展[J].国外医学遗传学分册,1999,222(2):82-86.
[30]O.Donnell CJ,Lindpaintner K,Larson MG,et al.Evidence for association and genetic linkage of the angiotensin-coverting enzyme locus with hypertension and blood pressure in men but not women in the Framingham heart study[J].Circulation,1998;97:1766
[31]Fomicheva EV,Gukova SP,Larionova-Vasina VI,et al.Gene-gene interaction in the RAS in the predisposition to myocardial infarction in elder population of St.Peterburg(Russia)[J].Mol Genet Metab,2001;69(1):76
[32]Keidar S,Kaplan M,Shapira L,et al.Low density lipoprotein isolated from patient with essential hypertension:a possible role for angiotensin Ⅱ[J].Atherosclerosis,1994;107: 71.
[33]Laurent S,Vanhoute P,Cavero I et al,The arterial wall a new pharmacological and the rapeutic target Fundamental Clincialpharmacology,1996,10:243.
[34]叶任高.内科学.人民卫生出版社.2002年7月第五版.
[35]赵光胜.现代高血压病学.人民军医出版社.1999年4月第一版.
[36]Knauf H.The role of low-dose diuretics in essential hypertension[J].J Cardiovasc Phatmacol,1993,22(suppl6):s1.
[37]Rrichard BNC and Graham BR.The use of moxonidine in the treatment of hypertension [J].J Iiypettens,1997(suppl1):s47.
[38]谢美花.抗高血压药物的发展和我院40年来研究概况[J].中国医药工业杂志,1997,28(2):70-74.
[39]陈燕.老年高血压患者的用药分析[J].中国药业,2002,11(11):77-78.
[40]潘发明,徐希平.高血压的药物基因组学的研究进展[J].国外医学遗传学分册,2004,27(3):191.
[41]田滏明,李振有,陈国伟.抗高血压药的新家族-血管紧张素受体阻断剂[J].国外医学内科学分册,1997,24(11):471-474.
[42]Taylor K,Paten RD,Smith J J,et al.Divergent efects of the angiotensin Ⅱ receptor antagonism on myocardial cellular prolific ration and clooagen deposition after myocardial infarction in rats[J].J Cardiovasc Pharmacol,1998,31:654-660.
[43]张建军.血管紧张素受体拮抗剂研究进展[J].国外医学抗生素分册,2001,22(3):134-139.
[44]Hermsmeyer K and Miyagawak K.Novel concepts in Cat'channel selectivity[J].J Hypertens,1997,15(suppl3):s5.
[45]Baumbach,Heistad D D.Remodeling of cerebral arterioles in chronic hypertension[J].Hypertension,1989,13(6Pt2):968-972.
[46]Dickhout J G,Lee R M.Structural and functional analysis of arteries from young spontanneously hypertensive rats[J].Hypertension,1997,29(3):781-789.
[47]Gibbons G H,Dzau V J.The emerging concept of vascular remodeling[J].N Eng1 J Med,1994,330(20):1 431-438
[48]Dzau V J,Gibbons G H,Morishita R,Pratt R E.New perspectives in hypertenion research: potenials of vascular biology [J]. Hypertension, 1994, 23 (6Pt2): 1 132-140.
[49] Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan M L. Cinelli A, etal.Vasular structure and functionsl alterations before and after the development of hypertension in spontaneously hypertensive rats[J]. AJH, 1994, 10(9Pt1): 1034-043.
[50]孙宁玲,徐成斌(主编)．今日高血压．中国医药科技出版社,2000,49-50．
[51] Langille B L. Blood flow induced remodeling of the artery wall. In: Bevan J A, Kaley G, Rubanyi G, eds:Flow Dependent regulation of vascular function[J]. New York NY: Oxford, 1995; 277-299.
[52] Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher A M. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis[J]. CircRes, 1998, 83(3): 334-341
[53] Krieger J E, Dzau V J. Molecular biology of hypertension[J]. Hypertension, 1991, 18 (3Spull): 1317
[54] Skalak T C, Price R J. Therole of mechanical stresses in microvascular remodeling[J]. Microcirculation, 1996,3(2): 143-165.
[55] Kamiya A, Togwa T. Adaptive regulation of wall shear stress to flow change in the canine carotid artery[J]. Am J Physiol, 1980, 239(1): H14-H21.
[56] Greene AS, Tonellato PJ, Lui J, Lombard H, Cowley AWJr. Microvascular rarefaction and tissue vascular resistance in hypertension[J]. AmJPhysiol, 1989, 256(1 Pt2): H126-H131.
[57] Khachigian LM, Andeson KR, Halnon NJ, Gimbrone MA Jr, Resnick N, Collins T. Egr-1 is activated in endothelial cells exposed to fluid shearstress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter[J]. Arterioscler Thromb VascBiol, 1997, 17(10): 280-286.
[58] Brothertom AFA, Ioark JC. Prostacyclinbiosynthesis incultured vascular endothelium is limited by deactivation of cyclo oxyenase[J]. J Clin Invest, 1983, 72: 1255.
[59] Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin coverting enzyme in the neointima after vascular injury: possible role in restenosis[J]. J Clin Invest, 1994, 93(1): 339-346.
[60] Haller H, Drab M, Luft FC. The role of hyperglyce mia and hyerinsuline mia in the path ogenesis of diabtic anfiopathy[J].Clin Nephrol,1996,46(4):246-255.
[61]Bayer IM,Adamson SL,Langille BL.Atrophic remodeling of the artery-cuffed artery[J].Arterioscler ThombVasc Biol,1999,19(6):1499-505.
[62]Fukuo K,Hata S,Suhara T,Nakahashi T,Shinto Y,Tsujimoto Y,etal.Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle[J].Hypertension,1996,27(3pt2):823-826.
[63]Nicholson D W,Thornberry N A.Caspases,killer proteases[J].Tremds Biochem Sci,1997,22(8):299-306.
[64]Pollman M J,Naumovski L,Gibbons G H.Vascular cell apoptosis:Cell-type specific modulation by transforming growth factor β 1 in endothelial cells versus smooth muscle cells circulation[J].1999,99(15):2019-026.
[65]Nagta S,Golstein P.The Fasdeath factor[J].Science,1995.267(5203):1449-456.
[66]Sara M.Suhara T.Walsh K.Vascular endothelial cells and smooth muscle cells differ in their expression of Fas and Fas ligand and in their sensitivity to Fas ligand-induced cell death:implications for vascular disease and therapy[J].Arterioscler Thromb Vasc Biol.2000,20(2):309-316.
[67]SataM,WalshK.OxidizedLDLactivatea Fas mediatedendothelialcellapoptosis[J].J Clin Invest,1998,102(9):1682-689.
[68]Perlamn H,Maillard L,Krasinski K,Waksh K.Evidence for the rapid onset of apoptosis in medial smoot hmuscle cells following balloon injury[J].Circulation,1997,95(4):981-987.
[69]邹飞燕,杨和平,涂玉林,杨永宗.动脉粥样硬化时平滑肌细胞凋亡的研究进展[J].中国动脉硬化杂志,1997,5(1):75-79.
[70]Miyashita T,Reed J C.Tumor suppressor p53 is a direct transcriptional activator of the human baxgene[J].Cell,1995,80(2):293-299.
[71]Gorski DH,Walsh K.The role of homeobox genes in vascular remodeling and angiogenesis[J].CircRes,2000,87(10):865-872.
[72]Drake C J,Cheresh DA,Little CD.Anantagonist of integrin α v β 3 prevents maturation of blood vessels during embryonic neovascularization[J].J Cell Sci.1995,108(pt7):2655-661.
[73] Kenneth MY. Fibronectin peptides in cell migration and wound repair[J]. JcliniInvest, 2000, 105(11): 1 507-509.
[74] Brekken RA, Sage EH. SPARC, a matricelluar protein: at the crossroads of cell matrix communication[J]. Matrix Biol, 2001,19(8): 816-827.
[75] Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structrue, function, and regulation during embeyonic developent and tissue remodeling[J]. DevDyn, 2000, 218(2): 235-259.
[76] Fernandez H A, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R, etal.Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1 [J]. J Surg Res, 1999, 82(2): 156-162.
[1]王跷娟,朱玲珍牛膝皂苷的化学成分研究[J]第四军医大学学报,1996,17(6):427-430.
[2]Nikolov S.Phan Thi Hos,Asenov I.A triterpene saponin from Achyranthes bidentata BI.[J]Farmat-siya,1991,41(2):14-18.
[3]郭胜民,车锝平,范晓雯等.怀牛膝皂苷A对动物子宫平滑肌的作用[J].西安医科大学学报.1997 18(2):216-218,225.
[4]孟大利.中药牛膝中的植物甾酮类成分.沈阳药科大学学报.2006,23(9):562-564,567
[5]韦松,梁鸿,赵玉英等.怀牛膝中化合物的分离鉴定[J].中国中药杂志.1997,22(5):293-295.
[6]高晓燕,王大为,李发美.牛膝中脱皮甾酮的含量测定及促成骨样细胞增殖活性[J].药学学报,2000,35(11):868.
[7]郑虎占、董泽宏、余靖.中药现代研究与应用[M].北京:学苑出版社.1997:1055-1073.
[8]Nicolov Stefan,Tbuan Ngugen,Zheljzlov Valocho.Flaroonoids from Achyranthes bidentata BI[C]Acta,Hoctic,1996:426(Iternational Symposiam on Medicinal and Aromatic Plantas,1995).
[9]时春娟,周永达等.牛膝多糖研究进展.中国新药杂志,2006,15(16):1330-1333.
[10]惠永正,邹卫,田庚元.牛膝根中一活性寡糖(ABS)的分离和结构研究[J].化学学报.1989,47(6):621-622.
[11]Yu Biao,Tian Zheng-Yuan,Hui Yong-Zheng.structral study on a bioactive fructan from the root of Achytanthes bidentata BI[J].Chin J Chem,1995,13(6):539-555.
[12]阎家麒,王九一.牛膝多糖工艺研究.中国医药工业杂志.1995;26(11):481-483.
[13]方积年.多糖分离纯化及其纯度鉴别,分子量测定[J].药学通报,1984,19(10):622.
[14]巢志茂,何波.尚儿金.怀牛膝挥发油成分分析.[J]天然产物研究与开发,1999,11(4):41-43.
[15]Rtra Parminder S.Alkaloids in two species of Achyranthes at different stages of their growth[J]Curr Trends Life Sct,1979,4(Avd,Ecol):81-85
[16]Bisht G,Sandhu H.Chemical Constituents and Antimicrobial Activity of Achyranthes Bidentata.J Indian Chem Soc 1990;67(12):1002-1008.
[17]Guptoi SS,Bhagwat AW,Ram AK.Cardiac stimldant activity of the asponin of achyranthes aspera(linn)[J].Indian J MedRes,1972,62(3):462.
[18]Ran AK.Effect of saponin of achyranthes aspera on thephosphorylase activity of rat heart[J].Indian J Physiol pharmacol,1971,15(3):107.
[19]Somova LO,Nadar A,Rammanan P,et al.Cardiovascular,antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension[J].Phytomedicine,2003,10(2-3):1151.
[20]Rodriguez - Rodriguez R,Herrera MD,Perona J S,etal 1Potential vasorelaxant effect s of oleanolic acid and erythrodiol,two t riterpenoids contained in'orujo'oliveoil,on rat aorta[J].BrJNutr,2004,92(4):6351.
[21]Somova L I,Shode FO,Mipando M.Cardiotonic andantidysrhyt hmic effects of oleanolic and ursolic acids,met hyl maslinate and uvaol[J].Phytomedici ne,2004,11(2-3):1211.
[22]江苏新医学院.中药大辞典.第1版.上海人民出版社,1977;417.
[23]王筠默.怀牛膝的药理研究[J].上海中医药杂志,1965;(3):31
[113]史玉芬,郑延彬.牛膝抗炎、抗菌作用的研究[J].中药通报,1988,13(7):4_4-47.
[24]张志英,王绍坤,郭连魁.牛膝抗衰老的生物化学研究[J].山西医学院学报,1995;26(1):4.
[25]魏振芳.怀牛膝对衰老小鼠SOD、LPO水平的影响[J].中草药,1985,16(6):11
[26]王猛,张新,孙艳涛.浅淡牛膝的化学成分与功效关系[J].山东医药工业,2003.22(2):44-45.
[27]张宇航,等.浅谈甜菜碱营养机理研究进展[J].中国糖料,2005,(2):53-54.
[28]郑金灿,陈忠科.怀牛膝的多倍体、单体和二倍体的药理作用比较[J].药学通报,1988,23(11):666.
[29]陈虹,石圣洪.中药川、怀牛膝对小鼠微循环及大鼠血液流变学的影响[J].中国微循环,2002,2(3):182-184
[30]江苏新医学院.中药大辞典.上海科学技术田黼.1996.417-418.
[1]Guptoi SS,Bhagwat AW,Ram AK.Cardiac stimldant activity of the asponin of achyranthes aspera(linn)[J].Indian J MedRes,1972,62(3):462.
[2]Ran AK.Effect of saponin of achyranthes aspera on thephosphorylase activity of rat heart [J].Indian J Physiol pharmacol,1971,15(3):107.
[3]Somova LO,Nadar A,Rammanan P,et al.Cardiovascular,antihyperlipidemic and antioxidant effects ofoleanolic and ursolic acids in experimental hypertension[J].Phytomedicine,2003,10(2-3):1151.
[4]Rodriguez - Rodriguez R,Herrera MD,Perona J S,etal 1Potential vasorelaxant effect s of oleanolic acid and erythrodiol,two t riterpenoids contained in'orujo'oliveoil,on rat aorta [J].BrJNutr,2004,92(4):6351.
[5]Somova L I,Shode FO,Mipando M.Cardiotonic andantidysrhyt hmic effects of oleanolic and ursolic acids,met hyl maslinate and uvaol[J].Phytomedici ne,2004,11(2-3):1211.
[6]张志英,王绍坤,郭连魁.牛膝抗衰老的生物化学研究[J].山西医学院学报,1995;26(1):4.
[7]魏振芳.怀牛膝对衰老小鼠SOD、LPO水平的影响[J].中草药,1985,16(6):11
[1]Tian B,Meng QC,Chen YE,et al.Blood pressures and cardiovasculal homeostasis in mice having reduced or absent angiotensinconverling enzyme gene function[J].Hypertens,1997,30;128-129.
[2]张静,李泓.舒脉灵冲剂对高血压的作用机制探讨[[J].交通医学,2000,14(2):123-124.
[2]董振华,范爱平.祝谌予教授治疗高血压病的经验介绍[J].中国医刊,1999,34(8):44-45.
[3]丁有钦.高血压病的中西医诊治[J].新中医,2000,32(10):40.
[4]陈四清.育阴潜阳、调气行血法治疗高血压病[J].江苏中医药,2004,25(12):41.
[5]严季澜.高血压病中医治疗.北京:中国医药科技出版社,1992:81.
[6]徐树楠,刘海丽.高血压病的中医病理学特点探微[J].中国中医基础医学杂志,2003,9(9):10.
[7]吴辉,冼绍祥,黄衍寿.血管活性物质与原发性高血压中医证型的关系[J].四川中医,2000,18(19):11.
[8]邓旭光.高血压病中医病机若干问题探讨[J].中医杂志,2001,42(4):197-199.
[9]陆广莘.高血压病中西医结合研究中的辨病和辨证问题[J].中医杂志,1980,21(5):11.
[10]孔炳耀.气血理论在高血压病研究中的应用[J].中国中医基础医学杂志,1998,4(9):52.
[11]李青鸟.原发性高血压病病因之我见[J].光明中医,2000,15(1):8-11.
[12]段学忠.益气活血法治疗老年高血压病的研究[J].山东中医药大学学报,1997,21(6):123.
[13]祝建华.从脾胃论治高血压病56例[J].四川中医,1997,15(1):26-27.
[14]邓铁涛.邓铁涛临床经验集要.北京冲国医药科技出版社,1981.
[15]郭乃光.健脾化湿法治疗无症状性高血压病30例[J].新中医,2000,32(10):35.
[16]邓旭光.高血压病中医病机若干问题探讨[J].中医杂志,2001,42(4):197-199.
[17]刘治主,牟建军.高血压病诊断治疗学.北京:北京医科大学,中国协和医科大学联合出版社,1998:16.
[18]王永先.中国内科学.上海:上海科学技术出版社,1997:337-342.
[19]李运伦,程立新.高血压病的病机病理刍议[J].中医研究,2000,13(1):7-8.
[20]冉旭.高血压病的病机探讨[J].湖北中医杂志,2002(3):11-12.
[21]龚一萍.以肝为中心论治高血压病的理论探讨[J].中国中医基础医学杂志,2000,6(11):29-30.
[22]衷敬柏,钱红宇,王英奇.105例中老年高血压病虚实分析[J].陕西中医,1996,17(3):103-104.
[23]柴瑞霁.柴浩然治疗高血压病的经验.山西中医,1994,10(4):10.
[24]肖梅芳.周端应用活血潜阳法治疗高血压病经验.上海中医药杂志,2004,38(4):12.
[25]李运伦.清热降压方治疗高血压病临床效应的比较研究[J].山东中医药大学学报,2001,25(1):18.
[26]李运伦.清旰宁心泻心解毒法治疗高血压病的探讨[J].山东中医药大学学报,2002,26(1):20.
[27]李运伦.高血压病气虚证证治规律探讨[J].山东中医杂志,2001,20(1):9-11.
[28]范平.温阳化瘀法治疗老年高血压病探析[J].山东中医杂志,1998,17(6):486.
[29]古炽明,丁有钦.高血压病证候文献分析述评[J].中医药学刊,2003,21(7):1156-1157.
[30]尚春生.温阳法治疗高血压病40例临床报道[J].实用中医内科杂志,1999,20(3):11.
[31]钱岳晟,张伟忠,周怀发,等.原发性高血压患者表型与中医体质分类关系的研究[J].中国中医基础医学杂志,2002,8(2):49.
[32]鞠大宏,韩学杰,谢雁鸣,等.高血压病从络论治探讨[J].中国中医基础医学杂志,2001,7(9):43.
[33]岳桂华,盖欣,张爱珍.自组织理论与高血压病初探[J].山东中医杂志,1999,18(6):245-246.
[34]蔡光先,朱克俭,韩育明,等.高血压病常见证候临床流行病学观察[J].中医杂志,1999,40(8):492.
[35]郑峰,胡世云,郭进建,等.高血压病中医辨证分析[J].河北中医,2000,22(9):651.
[36]袁成民,江涛.高血压病中医药研究进展[J].山东中医药大学学报,2002,26(3):235.
[37]刘小斌.邓铁涛教授诊疗经验整理研究[J].新中医,1998,30(3):6.
[38]丁有钦.高血压病的中西医诊治[J].新中医,2000,32(10):40.
[39]李运伦,曲政军.活血化瘀治疗高血压病的机理[J].山东中医药大学学报,1998,22(1):23.
[40]李运伦.黄连解毒汤加减治疗高血压病30例临床研究[J].国医论坛.2000,15(2):38-39.
[41]李运伦.理脾化湿法治疗原发性高血压35例[J].陕西中医,2004,25(2):136.
[42]高振华.高泳江辨治高血压病的经验.中医杂志,1997,38(11):654-655.
[43]雄上中,徐小周.辨证治疗老年高血压120例[J].四川中医,2001,8(19):38.
[44]张亚玲.高血压的辨证分型论治[J].衡阳医学院学报,1999,27(3):350.
[45]祝建华.从脾胃论治高血压病56例[J].四川中医,1997,15(1):26.
[46]甘业崇.镇肝熄风汤治疗轻中度高血压病157例[J].中国民间疗法,2005,13(1):53.
[47]蔡昌龙,李明月,邢之华等.天麻钩藤饮对肝阳上亢型高血压病患者血浆SOD、MDA的影响[J].家用医学杂志,2005,21(3):321.
[48]刘应柯,刘尚玲,郭桐生.参龙降压灵对自发性高血压大鼠血压及血浆ET、CGRP 含量的影响[J].第一军医大学学报,2000,20(2):180.
[49]李建平,严灿,邓中炎.活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究[J].中医杂志,2000,41(5):301.
[50]连娜,连秀峰,谢人明,等.心压平胶囊治疗高血压病的药效学研究[J].西北药学杂志,2000,15(1):17.
[51]吴伟,刘煜德,陈宏硅,等.补肾益心片对肾血管性高血压大鼠的降压作用及保护靶器官的研究[J].广州中医药大学学报,2001,18(1):63.
[52]刘守义,李秀芳,刘书宇,等.二麻降压冲剂降压作用的实验研究[J].中国中医药信息杂志,1999,5(9):22.
[53]廖圣宝,刘光伟,张雪冰,等.滋水降火饮对肾性高血压大鼠血清细胞因子水平的影响[J].中医药学报,2001,29(3):61.
[54]段学忠,杨丁友,孙西庆.益脉降压流浸膏对老年高血压患者血小板活化纤溶活性 及血管紧张素的影响[J].中国中西医结合杂志,2000,7(9):36.
[55]袁成民.八物降压冲剂治疗原发性高血压的临床及实验研究[J].山东中医药大学学报,1999,23(3):189.
[56]赖益忠.六味地黄丸(汤)现代研究新进展.中医药信息,1999,16(1):13.
[57]宋和鉴,钱世明,刑俊武.血压平滴鼻剂对自发性高血压大鼠血浆肾素血管紧张素的影响[J].中医药研究,2000,16(2):50-51.
[58]李武明,何香,谭元牛.复方杜仲降压片治疗高血压病45例分析[J].中医药学刊,2004,22(2):331-332.
[59]唐树德.首乌治疗早期肾脏损害血瘀型高血压患者28例[J].中国中西医结合杂志,1994,(5):302.
[60]潘志敏,经京,吕圭源.“血灵”的抗高血压临床研究及意义[J].浙江中医学院学报,1993,(6):31.
[61]罗伟.葛根素治疗高血压病的临床研究[J].中国中医基础医学杂志,2000,6(5):61.
[62]罗伟,李保东,杨瑞华,等.葛根素对高血压初患者血浆内皮素及血栓B_2、6-酮-前列腺素F_(1a)含量的影响[J].中国中西医结合杂志,2000,20(1):68-69.
[63]冯培芳,等.三七总皂甙改善高血压病左室舒张功能的临床研究.浙江中西医结合杂志,1996;6(2):65.
[64]龚铭,廖晓阳,辛茂顺.醋柳黄酮对高血压有利钙及胰岛素敏感性的影响[J].现代中西医结合杂志,2000,9(14):1303-1306.
[65]王鸿博.灯盏花对老年原发性高血压患者早期肾功能的影响J].现代中西医结合杂志,2000,9(18):1744-1745.
[66]施易安.足三里注射治疗高血压病40例[J].天津中医,2000,17(6):25.
[67]张登部,刘国真,侯凤琴,等.康为电子灸足三里对高血压患者血流变学及血压影响的观察[J].中国针灸,2000:685-686.
[68]刘幸娟.耳尖放血合耳穴贴压治疗高血压病[J].湖北中医杂志,2000,22(1):47.
[69]胡爱香,陈秀荣,杨永枝.足浴并按摩治疗高血压病40例.中医研究,2000,13(4):55.
[70]刘苏生.针刺人迎穴为主治疗高血压病56例.天津中医,2000,17(2):30.
[71]谢云.针刺耳压治疗原发性高血压病临床观察.中国针灸,2000,20(6):335-336.
[72]徐巧云,孙鸿杰.血液磁极化疗法治疗原发性高血压病143例疗效观察.中国实用内科杂志,2000,20(8):484-486.
[73]江苏新医学院 中药大辞典[M]上海:上海人民出版社,1977:2024.
[74]甄攀.粉防已碱的研究进展[J].张家口医学院学报,2004,21(2):79.
[75]黄志宏,汤泰秦,黄纳斯,等.川芎嗪对缺氧肺动脉高压大鼠血浆内皮素、降钙素基因相关肽水平的影响[J].广州中医药大学学报,1998,15(4):275-276.
[76]王峰,刘敏,杨连春,等.咖啡酸阿魏酸对高血压大鼠的降压作用[J].解放军药学学报,1999,15(5):1-4.
[77]王秋月,康健,李尔然,等.白花前胡提取物对缺氧性肺动脉高压病人血浆内皮素-1的影响[J].中国医科大学学报,2001,30(1):82-83.
[78]刘发,魏苑,杨新中.红花黄素对高血压大鼠的降压作用及对肾素、血管紧张素的影响[J].药学学报,1992,27(10):785.
[79]李志淮,杜冠华,张均田.丹酚酸A对高血压大鼠钠钾ATP酶活性的作用[J].中国中医药科技,1997,4(1):32.
[80]唐忠志,唐瑛.丹参对自发性高血压大鼠左室心肌病变及血液流变学的影响[J].第四军医大学学报,2004,25:100-103.
[81]程俊彦,熊玮,郑智,等.丹参逆转自发性高血压大鼠左室肥厚及其对血管紧张素Ⅱ受体1表达的影响[J].中国中西医结合急救杂志,2004,11:99-103.
[82]程俊彦,卢中秋,李章平,等.丹参预防自发性高血压大鼠左室肥厚及其对clos表达的影响[J].中国临床药理学与治疗学,2004,9:807-810.
[83]占成业,陶秀良,田橙,等.细胞黏附分子1在高血压左室肥厚发病中的作用及丹参酮ⅡA对其表达的影响[J].中国中西医结合急救杂志,2004,11:208-211.
[84]邓杰,熊玮,郑智.丹参对自发性高血压大鼠心肌细胞凋亡及基因蛋白表达的影响[J].江西医药,2003,38:322-324.
[85]李景新,薛冰,陈连璧.沙苑子总黄酮对高血压大鼠的降压作用及血管紧张素含量的影响[J].中国药理学与毒理学杂志,2002,16(5):338-339.
[86]耿秀芳,李桂芝,王守训.银杏叶总黄酮对ACE的活性的影响[J].吉林中医药,1993,(6):37.
[87]贺师鹏,靖宇,岳保珍.甘草次酸与大鼠肝膜血管紧张素Ⅱ受体相结合[J].中国药理学通报,1998,14(5):19-21.
[88]李连达.抗心肌缺血中药研究进展[J].中国中西医结合杂志,1987,7:57.
[89]刘祥秀,孔德明,张雅丽.单味中药黄芪对胰岛素抵抗并高血压防治作用的实验研究[J].贵阳中医学院学报.2005,21(1):22.
[90]贾月霞,时安云.枸杞多糖对肾性高血压大鼠血管活性物质的影响[J].北京医科大学学报.1997,29(5):429-432.
[91]陈素红,吕圭源,施斌,等.复方决明提取物的降压作用机制研究.中草药,2004,35(2):180.
[92]菪忠志,王启全,陈文敏,等.丹参对自发性高血压大鼠心肌Ⅰ和Ⅲ型胶原及局部醛固酮的影响[J].中华实用医学,2002,4(11):25.
[93]宋纯清,樊懿,黄伟晖,等.钩藤中不同成分降压作用的差异[J].中草药,2000,31(10):762.
[94]孔晓龙,蒋伟哲,黄仁彬,等.龙眼参对自发性高血压大鼠和SD大鼠血压的影响[J].中草药,2001,32(8):727-729.
[95]刘建斌,任江华.钩藤对自发性高血压大鼠心肌重构及原癌基因C-fos表达的影响[J].中国中医基础医学杂志.2000,6(5):40
[96]香川珠实.罗布麻叶提取物的降压作用[J].Natural Medicines.2004,58(3):109-112.
[97]玉从容,吕俊华.葛根素对胰岛素抵抗高血压模型大鼠血压和肾素血管紧张素系统的影响[J].四川中医,2005,23(4):20-22.
[98]关玉生.天麻钩藤饮治疗原发性高血压患者内皮素、降钙素基因相关肽的变化的研究[J].中药药理与临床,1997,13(6):45.
[99]刘保国,白宝银,施海法,等.加昧天麻钩藤饮对阴虚阳亢型高血压患者血浆ET、PRA、AngⅡ的影响[J].中国全科医学杂志,2000,3(3):190-191.
[100]龚一萍,倪美文,宋霄红.天麻钩藤饮对高血压肝阳上亢证大鼠胰岛素抵抗影响的实验研究[J].浙江中医学院学报,2005,29(2):62-64.
[101]金龙,周文泉.络活胶囊治疗痰瘀阻络型高血压病的临床研究[J].中国中西医结合杂志,2004,24(7):610-612.
[102]杨兴才.羚羊角治疗高血压病的临床研究[J].辽宁中医杂志,2004,31(11):911-912.
[103]周端,苑素云,顾仁提,等.活血潜阳胶囊改善高血压病血管重建的临床与实验研究[J].中国医药学报,2001,16(4):70-71.
[104]陈可冀.血府逐瘀滴丸防治血管成形术后再狭窄的研究[J].中国中医药科技,1997,4(3):173.
[105]宋和鉴,钱士明,邢俊武.血压平滴鼻剂对自发性高血压大鼠血压血浆肾素血管紧张素的影响[J].中医药研究,2000,16(2):50-51.
[106]李建平,严灿,邓中炎,等.活血祛痰治法及其组方预防自发性高血压大鼠心肌纤维化的实验研究[J].中医研究,1999,12(6):9-11.
[107]马杰,王普民,胡丽萍,等.心脑静片对实验性脑缺血及高血压的作用研究[J].中草药,2000,31(1):39-40.
[108]段学忠,孙西庆,李丁友.益脉降压流膏降压及调节内皮素与降钙素基因相关肽的实验研究[J].中国中医药科技,2000,7(3):143.
[109]刘文军,刘屏,袁默,等.益肾降压方对肾实质性高血压大鼠肾组织eNOS、ET-1及其mRNA表达的影响研究[J].中华中医药杂志,2005,20(9):528-530.
[110]刘景超,杨新年,肖华云,等.降压调脂胶囊对高血压大鼠血压及血清NO的影响[J].山东中医杂志,2001,20(4):236-237.
[111]贺林,王若光,尤昭玲,等.黄芪丹参注射液对妊娠高血压综合征大鼠血浆一氧化氮及肿瘤坏死因子的影响[J].湖南中医学院学报,2003,23(2):4-5.
[112]李运伦,汤钟娟.黄连清降合剂对自发性高血压大鼠血管平滑肌细胞生长因子表达的影响[J].山东中医药大学学报,2003,27(2):143-144.
[113]廖圣宝,刘光伟,张雪冰,等.滋水降火饮对肾性高血压大鼠血清细胞因子水平的影响[J].中医药学报,2001,29(3):60-61.
[114]夏洪生,田兵,张永峰,等.通脉Ⅰ号对自发性高血压大鼠血压及血管平滑肌细胞增殖的影响[J].深圳中西医结合杂志,2001,11(5):260-263.
[115]刘剑刚,史大卓,汪晓芳,等.愈心梗液对大鼠急性心肌梗死后早期心室重构的影响[J].中国中西医结合急救杂志,2001,8(2):76-78.
[116]罗心平,施海明,曾治宇,等.麝香保心丸对心肌梗塞后左室形态和功能影响的实验研究[J].中成药,2001,23(7):503-505.
[117]舒静,董耀荣.益气活血方治疗心室重构的临床研究[J].江苏中医,2000,21(9):13-15.
[118]潘毅,邓中炎,严灿.心肌康逆转高血压左室肥厚的临床研究[J].中国中医药科技,2001,8(4):213-214.
[119]田相同,赵龙梅.新加钩藤片对高血压病及左室肥厚的影响[J].山东中医杂志,2002,21(6):341-342.
[120]周建中,雷寒,陈运贞,等.灯盏细辛注射液对自发性高血压大鼠心室及血管重构的影响[J].中国中西医结合杂志,2002,22(2):122-125.
[121]王振涛,王硕仁,赵明镜,等.活血和益气方药对心肌梗死后左心衰大鼠左心室重构影响的比较研究[J].中国中西医结合杂志,2002,22(5):376-378.
[122]莫书荣,谢露,张士军.诺迪康对大鼠心肌超微结构的影响[J].广西中医药,2002,25(4):52-53.
[123]侯云生,何振山,齐书英,等.黄芪对急性心肌梗死后左室重构的实验研究[J].中国急救医学,2000,20(7):381-383.
[124]Wang H,Luo S D,Cai H S,et al.Antiarrhythmic effdct of diacetyl-Lineinine[J].Chin H osp Pharm J(中国医院药学杂志),2001,21(6):3281.
[125]Cao F.Huang C X.Jiang H.et al.Effets of diancetyl-Linesi-nine on sodium ion channel and L-type calcium ion channel in isolated ventricular myocytes[J].Med J W uhan Univ(武汉大学学报:医学版),2004,25(4):364-367.
[1266]Wang J L,Nong Y.Effects of Lien sin ine on action poten-tials and Ina,Lca-lin guinea pig ventricular myocytes[J].chin Tradit Herb Drugs(中药学),2000,31(3):194-196.
[127]Guo X G,Chen J Z.Effects of puerarin on L-typecalcium channel in isolated rat ventricularmyocytes[J].china J chin Mater Med(中国中药杂志),2004,29(3):247-250.
[128]Zhuang N N,Li Z C,Zhang A D,et al.The effects of oxy-mat rine on L-type calcium channel in isolated ventricular myocytes of guinea pig[J].Chin J Cardiac Pacing Electrophysiol(中国心脏起搏与心电生理杂志),2004,18(3):209-211.
[129]Sun H L,Xu C Q.Effects of oxymatrine on[Ca2+]in single ventricular myocyte of guinea pig[J].China J N at Med(国国天然药物),2004,39(4):264-266.
[130]Zhu X X,Li L D.The protective effects of vitexiarhamnoside(VR) on the cultured cardiac myocytes damaged by hypoxia and reoxygenation[J].China J N at Med(中国天然药物),2003,1(1):45-47.
[131]QiS Y,Liu K S,Wang Y G,et al.Effects of astragale on L-type calcium current ofr myocytes from rabbit infracted heart[J].Pharrn Chin Mater Med Clin(中国药理与临床),2003,19(1):17-19.
[132]何建国,荆志成,顾晴,等.缺氧性肺动脉高压大鼠泡内肺动脉与右心室胶原表达及黄芪的干预作用[J].中华医学杂志,1999,79(9):654-656.
[133]陈伟,顾仁樾,朱平,等.通心络调控心衰大鼠β受体系统抑制心室重构的实验研究[J].中国中医药科技,2002,9(5):274-275.
[134]邓中炎,严灿,潘毅,等.平肝益气、活血祛痰法逆转自发性高血压大鼠左心室重构的实验研究[J].中国中医药科技,2001,8(2):106-107.
[135]周迎春,赵锋利,陈镜合,等.开心胶囊对大鼠心梗后左室非梗塞区胶原改建的影响[J].广州中医药大学学报,2002,19(3):204-206.
[136]王振涛,王硕仁,李敏,等.活血益气注射液治疗心衰大鼠心气虚证的研究[J].中药药理与临床,2000,16(增刊):73-75.
[137]刘建斌,任江华.钩藤对自发性高血压大鼠心肌重构及原癌基因c-fbs表达的影响.中国中医基础医学杂志,2000,6(5):40-44.
[1]王萍,介建政.高血压流行病学[J].中国乡村医生杂志,2001,8:11.
[2]张维忠.2004年高血压研究的循证医学新进展[J].中国循证医学杂志,2005,5(3):185.
[3]于汇民,王兵,刘国仗.原发性高血压的病因及发病机制[J].新医学2003,34(3):135.
[4]王先梅,杨丽霞.原发性高血压发病机制的研究进展[J].西南国防医药,2005,15(1):98.
[5]沈利亚,仇克难.血管内皮舒张功能不全与高血压关系研究进展[J].江汉大学学报(自然科学版).2004,32(2):86.
[6]Bobik A,Grooms A,Millar T A,et al.Growth factor activity of endothelin on vascular smooth musle[J].Am J physiol,1990,258(3Ptl):408-415.
[7]Ashids T,Kawano Y,Yoshimi H,et al.Effects of ouabain and verapamil on endothelin-1induced contraction of mesenteric artery in young spontaneously hypertensive rats[J]J cardiovasc Pharmacol,1991,17(Suppl7):174-176.
[8]Gottsauner - Wolf M,Molitemo J,Lincoff AM,et al.Restenosis - an open file[J].Clin Cardiol,1996,19(5):347-356.
[9] Chabrier PE. Growth factors and vascular wall [J] . Int Angiol, 1996, 15(2): 100-103.
[10] Miyazaki H, Shibata T, Fujii N. Intracellular signaling pathways of angiotensin II receptor type 1 involved in the development of cardiovascular diseases[J]. Nippon Rinsho, 1998,56(7): 1906-1911.
[11] Inagami T, Eguchi S, Numaguchi K, et al. Cross - talk between angiotensin II receptors and the tyrosine kinases and phosphatases[J]. J Am Soc Nephrol, 1999, 10 (Suppl 11):S57 - 61.
[12] Liu G, Espinosa E, Oemar BS, et al. Bimodal effects of angiotensin II on migration of human and rat smooth muscle cells, direct stimulation and indirect inhibition via transforming growth factor- β 1[J]. Arterioscler Thromb Vasc Biol, 1997, 17(7): 1251 - 1257.
[13] Reaven GM. Role of insuiln in human disease[J]. Diabetes. 1988. 37(12): 1595.
[14] KatakamPV. UjhelyiMR. HoenigME, etal. Endothelialdys function precedes hypertension indiet-induced insulinre-sistance[J]. AmJPhysiol. 1998, 275(3): R788-792.
[15] Schachinger V, Britten MB, Zciher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease[J].Circulation, 2000,101(16):1899～1906.
[16] Vaziri ND, NiZ, Oveisi F, etal. Enhanced nitric oxide in activation and protein nitration by reactive oxygen species in renal insufficiency [J]. Hypertension. 2002,39(1):135～141.
[17] Giuseppe Lembo, Carmine Vecchione, Raffaele Izzo, etal. No radrenergic vasclar hyper-responsiveness in human hypertension is dependent on oxygen free radical impairment of nitric oxide activity [J].Circulation, 2000,102:552～557.
[18] Wassmann S, Laufs U, Baumer AT, et al. HMG CoA reductse inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species [J] Hypertension 2001,37(6):1450～1457.
[19] Lingyun W, Jacques DC. Effects of superoxide on signaling pathways in smooth cells from rats[J] Hypertension, 1999,34:1247—1253.
[20] Michael JR, Markewitz BA, Kohan E. Oxiod ativestress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells .[J] Am J Physiol, 1997, 273 : L768-L774.
[21]Tan Mianshin,Le Yanjiun,Shyijiang,et al.Oxidized low density liprotein stimulated endothelin-1 release and mRNA expression from rat med angial cells.[J]J lab Clin Med,1997,129(2):224-230.
[22]Ortiz MC.Manriquez MC,Romero JC,et al.Antioxidants block angiotenin Ⅱ induced increases in blood pressuer and endothelin.[J]Hypertension,2001 Sep;38(3Pt2):655-659.
[23]Liy.Liu J,Zhan X.Tyrosin ephosphorylation of cortactinisrequired for H2O2 mediated injury of human endothelial cells[J].J Biol Chem,2000,275(47):187-193.
[24]Abe J,Kusulma M,Ulevitch RJ,et al.Big mitogen actived protein kinasel(BKM1) is a redox-sensitive kinase[J].J Biol Chem 1996,273:16586-16590.
[25]Caper IR,Laursen JB,Fukai,et al.Vascular thrombin receptor regulation in hypertension rats[J].CircRes.1997.80:838-844.
[26]Kaikobad I rani.Oxidant sianaling in vascular cell growth,death,and survival,A review of the roles of reactive oxygen species in smooth muscle and endothelial cellmitogenic and apoptic signaling[J].CircRes,2000,87:179-183.
[27]Johns C,Ciavras 1,Handy DE,et al,Models of experimental Hypertension in mice[J].Hypertension,1996,28:1064.
[28]汤健,王瑜.肾素—血管紧张素系统分子生物学研究[J].基础医学与临床,1991,11(3):5-9.
[29]胡芳,肖君华.原发性高血压分子生物学的研究进展[J].国外医学遗传学分册,1999,222(2):82-86.
[30]O.Donnell CJ,Lindpaintner K,Larson MG,et al.Evidence for association and genetic linkage of the angiotensin-coverting enzyme locus with hypertension and blood pressure in men but not women in the Framingham heart study[J].Circulation,1998;97:1766
[31]Fomicheva EV,Gukova SP,Larionova-Vasina VI,et al.Gene-gene interaction in the RAS in the predisposition to myocardial infarction in elder population of St.Peterburg(Russia)[J].Mol Genet Metab,2001;69(1):76
[32]Keidar S,Kaplan M,Shapira L,et al.Low density lipoprotein isolated from patient with essential hypertension:a possible role for angiotensin Ⅱ[J].Atherosclerosis,1994;107: 71.
[33]Laurent S,Vanhoute P,Cavero I et al,The arterial wall a new pharmacological and the rapeutic target Fundamental Clincialpharmacology,1996,10:243.
[34]叶任高.内科学.人民卫生出版社.2002年7月第五版.
[35]赵光胜.现代高血压病学.人民军医出版社.1999年4月第一版.
[36]Knauf H.The role of low-dose diuretics in essential hypertension[J].J Cardiovasc Phatmacol,1993,22(suppl6):s1.
[37]Rrichard BNC and Graham BR.The use of moxonidine in the treatment of hypertension [J].J Iiypettens,1997(suppl1):s47.
[38]谢美花.抗高血压药物的发展和我院40年来研究概况[J].中国医药工业杂志,1997,28(2):70-74.
[39]陈燕.老年高血压患者的用药分析[J].中国药业,2002,11(11):77-78.
[40]潘发明,徐希平.高血压的药物基因组学的研究进展[J].国外医学遗传学分册,2004,27(3):191.
[41]田滏明,李振有,陈国伟.抗高血压药的新家族-血管紧张素受体阻断剂[J].国外医学内科学分册,1997,24(11):471-474.
[42]Taylor K,Paten RD,Smith J J,et al.Divergent efects of the angiotensin Ⅱ receptor antagonism on myocardial cellular prolific ration and clooagen deposition after myocardial infarction in rats[J].J Cardiovasc Pharmacol,1998,31:654-660.
[43]张建军.血管紧张素受体拮抗剂研究进展[J].国外医学抗生素分册,2001,22(3):134-139.
[44]Hermsmeyer K and Miyagawak K.Novel concepts in Cat'channel selectivity[J].J Hypertens,1997,15(suppl3):s5.
[45]Baumbach,Heistad D D.Remodeling of cerebral arterioles in chronic hypertension[J].Hypertension,1989,13(6Pt2):968-972.
[46]Dickhout J G,Lee R M.Structural and functional analysis of arteries from young spontanneously hypertensive rats[J].Hypertension,1997,29(3):781-789.
[47]Gibbons G H,Dzau V J.The emerging concept of vascular remodeling[J].N Eng1 J Med,1994,330(20):1 431-438
[48]Dzau V J,Gibbons G H,Morishita R,Pratt R E.New perspectives in hypertenion research: potenials of vascular biology [J]. Hypertension, 1994, 23 (6Pt2): 1 132-140.
[49] Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan M L. Cinelli A, etal.Vasular structure and functionsl alterations before and after the development of hypertension in spontaneously hypertensive rats[J]. AJH, 1994, 10(9Pt1): 1034-043.
[50]孙宁玲,徐成斌(主编)．今日高血压．中国医药科技出版社,2000,49-50．
[51] Langille B L. Blood flow induced remodeling of the artery wall. In: Bevan J A, Kaley G, Rubanyi G, eds:Flow Dependent regulation of vascular function[J]. New York NY: Oxford, 1995; 277-299.
[52] Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher A M. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis[J]. CircRes, 1998, 83(3): 334-341
[53] Krieger J E, Dzau V J. Molecular biology of hypertension[J]. Hypertension, 1991, 18 (3Spull): 1317
[54] Skalak T C, Price R J. Therole of mechanical stresses in microvascular remodeling[J]. Microcirculation, 1996,3(2): 143-165.
[55] Kamiya A, Togwa T. Adaptive regulation of wall shear stress to flow change in the canine carotid artery[J]. Am J Physiol, 1980, 239(1): H14-H21.
[56] Greene AS, Tonellato PJ, Lui J, Lombard H, Cowley AWJr. Microvascular rarefaction and tissue vascular resistance in hypertension[J]. AmJPhysiol, 1989, 256(1 Pt2): H126-H131.
[57] Khachigian LM, Andeson KR, Halnon NJ, Gimbrone MA Jr, Resnick N, Collins T. Egr-1 is activated in endothelial cells exposed to fluid shearstress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter[J]. Arterioscler Thromb VascBiol, 1997, 17(10): 280-286.
[58] Brothertom AFA, Ioark JC. Prostacyclinbiosynthesis incultured vascular endothelium is limited by deactivation of cyclo oxyenase[J]. J Clin Invest, 1983, 72: 1255.
[59] Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin coverting enzyme in the neointima after vascular injury: possible role in restenosis[J]. J Clin Invest, 1994, 93(1): 339-346.
[60] Haller H, Drab M, Luft FC. The role of hyperglyce mia and hyerinsuline mia in the path ogenesis of diabtic anfiopathy[J].Clin Nephrol,1996,46(4):246-255.
[61]Bayer IM,Adamson SL,Langille BL.Atrophic remodeling of the artery-cuffed artery[J].Arterioscler ThombVasc Biol,1999,19(6):1499-505.
[62]Fukuo K,Hata S,Suhara T,Nakahashi T,Shinto Y,Tsujimoto Y,etal.Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle[J].Hypertension,1996,27(3pt2):823-826.
[63]Nicholson D W,Thornberry N A.Caspases,killer proteases[J].Tremds Biochem Sci,1997,22(8):299-306.
[64]Pollman M J,Naumovski L,Gibbons G H.Vascular cell apoptosis:Cell-type specific modulation by transforming growth factor β 1 in endothelial cells versus smooth muscle cells circulation[J].1999,99(15):2019-026.
[65]Nagta S,Golstein P.The Fasdeath factor[J].Science,1995.267(5203):1449-456.
[66]Sara M.Suhara T.Walsh K.Vascular endothelial cells and smooth muscle cells differ in their expression of Fas and Fas ligand and in their sensitivity to Fas ligand-induced cell death:implications for vascular disease and therapy[J].Arterioscler Thromb Vasc Biol.2000,20(2):309-316.
[67]SataM,WalshK.OxidizedLDLactivatea Fas mediatedendothelialcellapoptosis[J].J Clin Invest,1998,102(9):1682-689.
[68]Perlamn H,Maillard L,Krasinski K,Waksh K.Evidence for the rapid onset of apoptosis in medial smoot hmuscle cells following balloon injury[J].Circulation,1997,95(4):981-987.
[69]邹飞燕,杨和平,涂玉林,杨永宗.动脉粥样硬化时平滑肌细胞凋亡的研究进展[J].中国动脉硬化杂志,1997,5(1):75-79.
[70]Miyashita T,Reed J C.Tumor suppressor p53 is a direct transcriptional activator of the human baxgene[J].Cell,1995,80(2):293-299.
[71]Gorski DH,Walsh K.The role of homeobox genes in vascular remodeling and angiogenesis[J].CircRes,2000,87(10):865-872.
[72]Drake C J,Cheresh DA,Little CD.Anantagonist of integrin α v β 3 prevents maturation of blood vessels during embryonic neovascularization[J].J Cell Sci.1995,108(pt7):2655-661.
[73] Kenneth MY. Fibronectin peptides in cell migration and wound repair[J]. JcliniInvest, 2000, 105(11): 1 507-509.
[74] Brekken RA, Sage EH. SPARC, a matricelluar protein: at the crossroads of cell matrix communication[J]. Matrix Biol, 2001,19(8): 816-827.
[75] Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structrue, function, and regulation during embeyonic developent and tissue remodeling[J]. DevDyn, 2000, 218(2): 235-259.
[76] Fernandez H A, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R, etal.Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1 [J]. J Surg Res, 1999, 82(2): 156-162.
[1]王跷娟,朱玲珍牛膝皂苷的化学成分研究[J]第四军医大学学报,1996,17(6):427-430.
[2]Nikolov S.Phan Thi Hos,Asenov I.A triterpene saponin from Achyranthes bidentata BI.[J]Farmat-siya,1991,41(2):14-18.
[3]郭胜民,车锝平,范晓雯等.怀牛膝皂苷A对动物子宫平滑肌的作用[J].西安医科大学学报.1997 18(2):216-218,225.
[4]孟大利.中药牛膝中的植物甾酮类成分.沈阳药科大学学报.2006,23(9):562-564,567
[5]韦松,梁鸿,赵玉英等.怀牛膝中化合物的分离鉴定[J].中国中药杂志.1997,22(5):293-295.
[6]高晓燕,王大为,李发美.牛膝中脱皮甾酮的含量测定及促成骨样细胞增殖活性[J].药学学报,2000,35(11):868.
[7]郑虎占、董泽宏、余靖.中药现代研究与应用[M].北京:学苑出版社.1997:1055-1073.
[8]Nicolov Stefan,Tbuan Ngugen,Zheljzlov Valocho.Flaroonoids from Achyranthes bidentata BI[C]Acta,Hoctic,1996:426(Iternational Symposiam on Medicinal and Aromatic Plantas,1995).
[9]时春娟,周永达等.牛膝多糖研究进展.中国新药杂志,2006,15(16):1330-1333.
[10]惠永正,邹卫,田庚元.牛膝根中一活性寡糖(ABS)的分离和结构研究[J].化学学报.1989,47(6):621-622.
[11]Yu Biao,Tian Zheng-Yuan,Hui Yong-Zheng.structral study on a bioactive fructan from the root of Achytanthes bidentata BI[J].Chin J Chem,1995,13(6):539-555.
[12]阎家麒,王九一.牛膝多糖工艺研究.中国医药工业杂志.1995;26(11):481-483.
[13]方积年.多糖分离纯化及其纯度鉴别,分子量测定[J].药学通报,1984,19(10):622.
[14]巢志茂,何波.尚儿金.怀牛膝挥发油成分分析.[J]天然产物研究与开发,1999,11(4):41-43.
[15]Rtra Parminder S.Alkaloids in two species of Achyranthes at different stages of their growth[J]Curr Trends Life Sct,1979,4(Avd,Ecol):81-85
[16]Bisht G,Sandhu H.Chemical Constituents and Antimicrobial Activity of Achyranthes Bidentata.J Indian Chem Soc 1990;67(12):1002-1008.
[17]Guptoi SS,Bhagwat AW,Ram AK.Cardiac stimldant activity of the asponin of achyranthes aspera(linn)[J].Indian J MedRes,1972,62(3):462.
[18]Ran AK.Effect of saponin of achyranthes aspera on thephosphorylase activity of rat heart[J].Indian J Physiol pharmacol,1971,15(3):107.
[19]Somova LO,Nadar A,Rammanan P,et al.Cardiovascular,antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension[J].Phytomedicine,2003,10(2-3):1151.
[20]Rodriguez - Rodriguez R,Herrera MD,Perona J S,etal 1Potential vasorelaxant effect s of oleanolic acid and erythrodiol,two t riterpenoids contained in'orujo'oliveoil,on rat aorta[J].BrJNutr,2004,92(4):6351.
[21]Somova L I,Shode FO,Mipando M.Cardiotonic andantidysrhyt hmic effects of oleanolic and ursolic acids,met hyl maslinate and uvaol[J].Phytomedici ne,2004,11(2-3):1211.
[22]江苏新医学院.中药大辞典.第1版.上海人民出版社,1977;417.
[23]王筠默.怀牛膝的药理研究[J].上海中医药杂志,1965;(3):31
[113]史玉芬,郑延彬.牛膝抗炎、抗菌作用的研究[J].中药通报,1988,13(7):4_4-47.
[24]张志英,王绍坤,郭连魁.牛膝抗衰老的生物化学研究[J].山西医学院学报,1995;26(1):4.
[25]魏振芳.怀牛膝对衰老小鼠SOD、LPO水平的影响[J].中草药,1985,16(6):11
[26]王猛,张新,孙艳涛.浅淡牛膝的化学成分与功效关系[J].山东医药工业,2003.22(2):44-45.
[27]张宇航,等.浅谈甜菜碱营养机理研究进展[J].中国糖料,2005,(2):53-54.
[28]郑金灿,陈忠科.怀牛膝的多倍体、单体和二倍体的药理作用比较[J].药学通报,1988,23(11):666.
[29]陈虹,石圣洪.中药川、怀牛膝对小鼠微循环及大鼠血液流变学的影响[J].中国微循环,2002,2(3):182-184
[30]江苏新医学院.中药大辞典.上海科学技术田黼.1996.417-418.
[1]Guptoi SS,Bhagwat AW,Ram AK.Cardiac stimldant activity of the asponin of achyranthes aspera(linn)[J].Indian J MedRes,1972,62(3):462.
[2]Ran AK.Effect of saponin of achyranthes aspera on thephosphorylase activity of rat heart [J].Indian J Physiol pharmacol,1971,15(3):107.
[3]Somova LO,Nadar A,Rammanan P,et al.Cardiovascular,antihyperlipidemic and antioxidant effects ofoleanolic and ursolic acids in experimental hypertension[J].Phytomedicine,2003,10(2-3):1151.
[4]Rodriguez - Rodriguez R,Herrera MD,Perona J S,etal 1Potential vasorelaxant effect s of oleanolic acid and erythrodiol,two t riterpenoids contained in'orujo'oliveoil,on rat aorta [J].BrJNutr,2004,92(4):6351.
[5]Somova L I,Shode FO,Mipando M.Cardiotonic andantidysrhyt hmic effects of oleanolic and ursolic acids,met hyl maslinate and uvaol[J].Phytomedici ne,2004,11(2-3):1211.
[6]张志英,王绍坤,郭连魁.牛膝抗衰老的生物化学研究[J].山西医学院学报,1995;26(1):4.
[7]魏振芳.怀牛膝对衰老小鼠SOD、LPO水平的影响[J].中草药,1985,16(6):11
[1]Tian B,Meng QC,Chen YE,et al.Blood pressures and cardiovasculal homeostasis in mice having reduced or absent angiotensinconverling enzyme gene function[J].Hypertens,1997,30;128-129.
[2]张静,李泓.舒脉灵冲剂对高血压的作用机制探讨[[J].交通医学,2000,14(2):123-124.